Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer

No abstract is available for this paper.

• Publication year

  2017

• Venue

  International Journal of Cancer

• Publication date

  2017-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ijc.30616PMID 28120435
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers

  2016cited by this paper
• Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer

  2016cited by this paper
• Abstract P5-08-02: Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score result: 5-year KM estimate for breast cancer specific survival with recurrence score results ≤30 is >98%

  2016cited by this paper
• Twenty‐one–gene recurrence score assay in BRCA‐associated versus sporadic breast cancers: Differences based on germline mutation status

  2016influential reference
• Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations

  2016influential reference
• Oncotype DX scores in BRCA1 and BRCA2 associated breast cancer.

  2015influential reference
• Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.

  2012cited by this paper
• Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.

  2011cited by this paper
• Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

  2011cited by this paper
• Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features

  2010cited by this paper
• Molecular characterization of male breast cancer by standardized quantitative RT-PCR analysis: First large genomic study of 347 male breast cancers compared to 82,434 female breast cancers.

  2009cited by this paper
• Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.

  2007influential reference
• Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.

  2006cited by this paper
• Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

  2006cited by this paper

• Oncotype DX Recurrence Score and Germline BRCA Variants in Patients with HR-Positive/HER2-Negative Early Breast Cancer: A Retrospective Observational Study

  2025cites this paper
• Current controversies in the use of Oncotype DX in early breast cancer.

  2025cites this paper
• Refining prognostic tools for luminal breast cancer: genetic insights and comprehensive analysis

  2025cites this paper
• ER-positive and BRCA2-mutated breast cancer: a literature review

  2024cites this paper
• HR-positive/HER2-negative breast cancer arising in patients with or without BRCA2 mutation: different biological phenotype and similar prognosis

  2024cites this paper
• BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization

  2024cites this paper
• Progress and prospects in research and clinical practice of hormone receptor-positive, HER-2-negative breast cancer with BRCA1/2 mutations

  2023cites this paper
• Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation

  2023cites this paper
• Distinct breast cancer phenotypes in BRCA 1/2 carriers based on ER status

  2023cites this paper
• Prognostic and Predictive Biomarkers in Familial Breast Cancer

  2023cites this paper
• Estrogen receptor-positive breast cancer and adverse outcome in BRCA2 mutation carriers and young non-carrier patients

  2023cites this paper
• Systemic treatment of breast cancer in young patients with a germline mutation in the BRCA1 and BRCA2 genes

  2023cites this paper
• Clinical outcomes and Oncotype DX Breast Recurrence Score® in early‐stage BRCA‐associated hormone receptor‐positive breast cancer

  2022cites this paper
• Breast Cancer with Low Recurrence Score on Oncotype DX©: Interplay Between Early Recurrence, Lobular Histology and BRCA Mutation

  2022cites this paper
• Effectiveness of Secondary Risk–Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study

  2022cites this paper
• A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status

  2021cites this paper
• Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants

  2021cites this paper
• OncotypeDX© Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis.

  2021cites this paper
• Ethnicity, recurrence score distribution, and clinical outcomes in ER + HER2‐negative breast cancer patients in Israel: A registry analysis

  2020cites this paper
• Systemic Therapies of Young Breast Cancer Patients at High Genetic Risk

  2020cites this paper
• Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score.

  2020cites this paper
• BRCA Mutation Association with Recurrence Score and Discordance in a Large Oncotype Database

  2020cites this paper
• Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes

  2020cites this paper
• Oestrogen receptor status and survival in women with BRCA2-associated breast cancer

  2019cites this paper
• An integrative view on breast cancer signature panels

  2019cites this paper
• Patterns of recurrence and metastasis in BRCA1/BRCA2‐associated breast cancers

  2019cites this paper
• Breast Cancer in BRCA 1 / 2 Mutation Carriers – Do We Treat It Differently ? Focus on Systemic Ther apy for BRCA 1 / 2 Associated Breast Cancer

  2019cites this paper
• Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.

  2019cites this paper
• Targeting DNA repair in breast cancer.

  2019cites this paper
• Molecular Characterization and Mortality From Breast Cancer in Men.

  2018cites this paper
• Verification of a Western Nomogram for Predicting Oncotype DX™ Recurrence Scores in Korean Patients with Breast Cancer

  2018cites this paper
• PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside

  2018cites this paper
• The 21-Gene Recurrence Score in Male Breast Cancer

  2018cites this paper